BlueRock Therapeutics Phase I Clinical Trial for Bemdaneprocel for Parkinson ’s Disease Continues to Show Positive Trends at 18 Months

Berlin, Germany and Cambridge, MA USA, March 6, 2024– Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of 18-month data from...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials